Investment
Features
FeesSafety
Academy
More
Pluang+

New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions

Market News
11 Oct 2026
Na
View Source
Bullish
New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions

Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs rose to 41.9%, the highest reported for any non-invasive blood test in a pivotal study. Overall colorectal cancer detection remained strong at 80.4% sensitivity with 90% specificity. These improvements could make colorectal cancer screening more accessible and effective for unscreened populations, with detailed results to be presented at ACG 2026.

Freenome's new colorectal cancer screening test shows improved sensitivity for advanced precancerous lesions, reaching 18.2% compared to 13.7% previously. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 11, 2026 23:11 WIB: out of 128 priced US health-sector stocks, 109 rose and 18 fell. Notable movers include Moderna (MRNA) up 14.21% at USD 225.00 with a typical hold time of 59 days, Heron Therapeutics (HRTX) up 13.37% at USD 0.41, and Humana (HUM) up 11.34% at USD 431.03.

More News

Stellantis unveils six bold concept cars ahead of the Paris Motor Show, showcasing future mobility and design innovation.

Stellantis unveils six bold concept cars ahead of the Paris Motor Show, showcasing future mobility and design innovation.

Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...

Market News
Bullish
37 minutes ago
Encaleret boosts bone turnover and improves symptoms in ADH1 patients, with FDA Priority Review underway.

Encaleret boosts bone turnover and improves symptoms in ADH1 patients, with FDA Priority Review underway.

BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...

Company Fundamentals
Bullish
2 hours ago
Bitcoin surges past $84,000, triggering $83M in short position liquidations amid volatile crypto trading.

Bitcoin surges past $84,000, triggering $83M in short position liquidations amid volatile crypto trading.

Bitcoin's price climbed above $84,000, briefly reaching highs around $85,200, driven by a sharp rally that forced nearly $83 million in short positions to close. This liquidation event highlights how leveraged trading can amplify market volatility, a...

Market News
Bullish
4 hours ago
Bitcoin tops $84,000, liquidating nearly $83M in short bets amid strong rally

Bitcoin tops $84,000, liquidating nearly $83M in short bets amid strong rally

Bitcoin surged above $84,000, triggering nearly $83 million in short position liquidations as bearish traders were forced to exit. This price level has previously caused significant short squeezes, including a $262 million liquidation event in Septem...

Market News
Bullish
4 hours ago
Big banks kick off earnings season; Taiwan Semiconductor eyes strong AI chip demand amid inflation watch.

Big banks kick off earnings season; Taiwan Semiconductor eyes strong AI chip demand amid inflation watch.

Earnings season heats up with major banks like JPMorgan, Goldman Sachs, and Wells Fargo reporting strong results, highlighting robust market and investment banking revenue. Taiwan Semiconductor is expected to see strong demand for AI chips, with grow...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App